Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Mar 31, 2020 at 11:02 AM.

  1. #1 cafead, Mar 31, 2020 at 11:02 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,932
    Likes Received:
    3
    via Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

    In what may be a relief for some investors, its big, highly anticipated KRAS drug AMG 510 is already fully enrolled, and the company doesn’t see any “significant delays” for results here. (Though that line doesn’t rule out any smaller delays.)

    article source
     
    Quote

Reply to Thread